Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
August 10, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen to Present at the Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
August 08, 2016 16:01 ET | Source: Achaogen Inc.

Achaogen Reports Second Quarter 2016 Financial Results and Provides Corporate Update

-- Enrollment in Phase 3 EPIC registration clinical trial of plazomicin maintained momentum; top-line results from EPIC expected in the first quarter of 2017 ---- Secured $55 million in additional...
July 15, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen to Host Key Opinion Leader Meeting on Multi-Drug Resistant Infections on July 19, 2016 in New York

SOUTH SAN FRANCISCO, Calif., July 15, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
July 06, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 24, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., June 24, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 20, 2016 08:30 ET | Source: Achaogen Inc.

Achaogen’s Plazomicin Highlighted in Multiple Presentations at ASM Microbe 2016 Outlining Bactericidal Activity Against MDR Pathogens

SOUTH SAN FRANCISCO, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 09, 2016 08:30 ET | Source: Achaogen Inc.

Achaogen Announces Plazomicin Data Presentations at ASM Microbe 2016 Annual Meeting

SOUTH SAN FRANCISCO, Calif., June 09, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 03, 2016 08:00 ET | Source: Achaogen, Inc.

Achaogen Adds Tobin Schilke as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 03, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
June 02, 2016 08:00 ET | Source: Achaogen, Inc.

Achaogen Awarded $20 Million Contract Option by BARDA to Support Development of Plazomicin for Multi-Drug Resistant Gram-Negative Infections

SOUTH SAN FRANCISCO, Calif., June 02, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...